Patent intelligence · US
US 12030970
Curable composition and stereolithographic resin composition comprising same
Curable composition and stereolithographic resin composition comprising same
Patent details — US 12030970
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 9, 2024
- Expiration
- Jul 4, 2044
- Applicant
- KURARAY CO., LTD.
- Claims
- 18
- CPC classes
- A61K, A61K6/62, A61K6/887
Quick answer
US 12030970 (Curable composition and stereolithographic resin composition comprising same) is held by KURARAY CO., LTD.. Status: granted. Granted Jul 9, 2024. Expires Jul 4, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- KURARAY CO., LTD.
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61K, A61K6/62, A61K6/887
More from KURARAY CO., LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12410184
Crystalline forms of a menin inhibitor
granted -
US 12377026
Dental adhesive material kit
granted -
US 12358210
Resin composition for stereolithography
granted -
US 12344691
Resin composition for stereolithography
granted -
US 12214061
Adhesive composition for dental use
granted -
US 12208148
Dental restorative curable composition
granted -
US 12145888
Zirconia molded body and pre-sintered body capable of being sintered in short time
granted -
US 12138325
Dental composition
granted
Frequently asked questions
What is US patent 12030970?
US 12030970 (Curable composition and stereolithographic resin composition comprising same) is held by KURARAY CO., LTD.. Status: granted. Granted Jul 9, 2024. Expires Jul 4, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12030970?
KURARAY CO., LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 132 pharmaceutical patents for this assignee.
When does US 12030970 expire?
Our index shows an expiration date of Jul 4, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.